ArticleBMC microbiology2025
Fluconazole-resistant vulvovaginal candidiasis in reproductive-age women: a study from Himalayan country.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Species Distribution ofPathogens (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVulvovaginal candidiasis is the second most common fungal infections among reproductive-age women. These conditions are commonly treated with the azole derivatives administered locally or systemically, most commonly fluconazole (FCZ). This study aimed to determine the prevalence of Candida spp. infection, access antifungal resistance, and detect different enzymes in Nepalese women of reproductive-age.
methodA cross-sectional study was conducted from Narayani Hospital, Parsa, Nepal. Duplet 345 high vaginal swabs and mid-steam urine samples, demographic, comorbidities, and symptoms, were collected from reproductive-age Nepalese women suffering from vaginitis. Bacteria and Candida spp. were isolated by culture, and further identification of Candida spp. was achieved through molecular sequencing of the Internal Transcribed Spacer region using universal primer sets. Antifungal susceptibility tests, followed by Kirby-Bauer disk diffusion method, and minimum inhibitory concentration of FCZ were determined according to Clinical Laboratory and Standards Institute guidelines. Enzymatic activity was also determined using a semi-quantitative method.
resultsThe prevalence of vulvovaginal candidiasis was 6.9%, and Candida albicans (44%) was the leading cause of infection, followed by C. metapsilosis (36%) and C. tropicalis (8%). A correlation was established between vulvovaginal candidiasis and douching, spraying, or washing (COR 0.36, 95% CI 0.13, p value = 0.05). All isolated Candida spp. were resistant to FCZ, and 8% of C. albicans and 4% of C. metapsilosis produce hemolysin, esterase and phospholipase activity.
conclusionsVulvovaginal candidiasis is a significant cause of morbidity, and resistance to FCZ, as well as enzyme produced, indicate a potential challenge for standard treatment approaches. Besides C. albicans, non-albicans Candida are also a possible threat to vulvovaginal candidiasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.